As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...
Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin ...
Biosimilars at the Crossroads: A $234 Billion Opportunity or a Missed Chance for Healthcare Savings?
The U.S. stands at a crossroads in light of rising drug prices and it is unclear what the future will hold in answer to the rising drug costs. Biologic medicines have rapidly expanded available ...
BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully ...
The FDA is considering a change in biosimilar policy that could make things a lot easier for a whole host of stakeholders that include the companies that develop these complex follow-on biologic drugs ...
Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these ...
Lowering the prices of prescription drugs has been high on United States President Donald Trump’s agenda since he took office in January. He has taken a number of steps, including striking deals with ...
Ondibta is approved for the treatment of diabetes mellitus in adults, adolescents and in children aged two years old and ...
This past year contained a number of significant developments in litigation involving biologics and biosimilars. The following is a recap of the ...
The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...
Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of Nivolumab, in India, priced at nearly one-fourth of the reference drug to expand access to cancer immunotherapy.
India’s Zydus Lifesciences, an innovation-led life-sciences company with an international presence, has launched the world’s first biosimilar of nivolumab in India under the brand name Tishtha, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback